GLP-1 users already have slowed digestion at times from the drug, and fat can slow it down even more, Roque explains
Warning: Risk of Thyroid C-Cell Tumors In studies with mice and rats, tirzepatide (the active ingredient in Zepbound and Mounjaro) caused thyroid tumors, including thyroid cancer
Switching from injections to drops The most common reason for switching is needle fatigue or preference for oral administration
Recently, a real-world study showing association between incretin-based therapy and changes in taste perception with GLP-1 or dual GLP-1/GIP-RAs usage for around 40 weeks reported that independently to weight loss, there was an increase in sweet perception intensity up to 4.7 times and salt perception up to 3.2 times in around 20% of the participants, resulting as well in earlier satiety, and reduction of hunger and craving due to a major sensibilization to both flavors with any of these medication, although they did not mention further impact in weight loss or BMI change (170)
Women with obesity and/or diabetes (the population using GLP-1 medications) already face higher pregnancy complication rates even without medication
